Clio Cosmetics클리오

Clio Cosmetics shows solid trailing profit on a 2026 rebound, but the shares are down 18.6% over the past year.

Trailing twelve-month revenue to H1 2026 is about ₩330B with an operating margin of 8.9%, up from 5.0% in 2025. The company carries very little debt and holds about ₩126B in cash, and it trades at a P/E of 6.9 and P/B of 0.8. The data does not include analyst ratings or consensus forecasts.

What stands out

• Revenue fell 6.4% in 2025 to ₩329B, but trailing revenue to H1 2026 is roughly flat at ₩330B.
• Trailing operating income of ₩29B and net income of ₩30B are well above the 2025 full-year levels of ₩16B and ₩14B.
• Borrowings are negligible at about ₩72M against cash of about ₩126B, and liabilities are 29.7% of equity.
• The filings show a preliminary earnings release, a half-year report and an amended half-year report, all dated August 2026.
• Shares closed at ₩11,340, below the 52-week high of ₩15,330, and the model's base-case DCF value is ₩21,510, though this is a model output, not a target.
• No recent news headlines or investor flow and foreign ownership data were available.

What to watch

• Trailing net income is above operating income, so check how much of the H1 2026 profit came from non-operating items, which the data does not break out.
• The amended half-year report filed on 14 August 2026: check what changed versus the original.
• Exposure to China and duty-free channels is not detailed in the data, so the export mix may be a risk to monitor in upcoming filings.